Literature DB >> 11500413

Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells.

G I Byrne1, S P Ouellette, Z Wang, J P Rao, L Lu, W L Beatty, A P Hudson.   

Abstract

Chlamydia pneumoniae causes community-acquired pneumonia and is associated with several chronic diseases, including asthma and atherosclerosis. The intracellular growth rate of C. pneumoniae slows dramatically during chronic infection, and such persistence leads to attenuated production of new elementary bodies, appearance of morphologically aberrant reticulate bodies, and altered expression of several chlamydial genes. We used an in vitro system to further characterize persistent C. pneumoniae infection, employing both ultrastructural and transcriptional activity measurements. HEp-2 cells were infected with C. pneumoniae (TW-183) at a multiplicity of infection of 3:1, and at 2 h postinfection gamma interferon (IFN-gamma) was added to the medium at 0.15 or 0.50 ng/ml. Treated and untreated cultures were harvested at several times postinfection. RNA was isolated and reverse transcribed, and reverse transcription (RT)-PCR analyses targeting primary transcripts from chlamydial rRNA operons as well as dnaA, polA, mutS, minD, ftsK, and ftsW mRNA were done. Some cultures were fixed and stained for electron microscopic analysis, and a real-time PCR assay was used to assess relative chlamydial chromosome accumulation under each culture condition. The latter assays showed that bacterial chromosome copies accumulated severalfold during IFN-gamma treatment of infected HEp-2 cells, although less accumulation was observed in cells treated with the higher dose. Electron microscopy demonstrated that high-dose IFN-gamma treatment elicited aberrant forms of the bacterium. RT-PCR showed that chlamydial primary rRNA transcripts were present in all IFN-gamma-treated and untreated cell cultures, indicating bacterial metabolic activity. Transcripts from dnaA, polA, mutS, and minD, all of which encode products for bacterial chromosome replication and partition, were expressed in IFN-gamma-treated and untreated cells. In contrast, ftsK and ftsW, encoding products for bacterial cell division, were expressed in untreated cells, but expression was attenuated in cells treated with low-dose IFN-gamma and absent in cells given the high dose of cytokine. Thus, the development of persistence included production of transcripts for DNA replication-related, but not cell division-related, genes. These results provide new insight regarding molecular activities that accompany persistence of C. pneumoniae, as well as suggesting requirements for reactivation from persistent to productive growth.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500413      PMCID: PMC98653          DOI: 10.1128/IAI.69.9.5423-5429.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green.

Authors:  M Hiratsuka; Y Agatsuma; M Mizugaki
Journal:  Mol Genet Metab       Date:  1999-11       Impact factor: 4.797

Review 2.  Background and current knowledge of Chlamydia pneumoniae and atherosclerosis.

Authors:  J T Grayston
Journal:  J Infect Dis       Date:  2000-06       Impact factor: 5.226

Review 3.  Control of cyclic chromosome replication in Escherichia coli.

Authors:  H Bremer; G Churchward
Journal:  Microbiol Rev       Date:  1991-09

4.  Persistent infection with Chlamydia pneumoniae following acute respiratory illness.

Authors:  M R Hammerschlag; K Chirgwin; P M Roblin; M Gelling; W Dumornay; L Mandel; P Smith; J Schachter
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

5.  Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

Authors:  P Saikku; M Leinonen; K Mattila; M R Ekman; M S Nieminen; P H Mäkelä; J K Huttunen; V Valtonen
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

6.  Chlamydia pneumoniae present in the human synovium are viable and metabolically active.

Authors:  H C Gérard; H R Schumacher; H El-Gabalawy; R Goldbach-Mansky; A P Hudson
Journal:  Microb Pathog       Date:  2000-07       Impact factor: 3.738

7.  Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma.

Authors:  D L Hahn; R W Dodge; R Golubjatnikov
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

Review 8.  Chlamydia and associated arthritis.

Authors:  R D Inman; J A Whittum-Hudson; H R Schumacher; A P Hudson
Journal:  Curr Opin Rheumatol       Date:  2000-07       Impact factor: 5.006

9.  In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model.

Authors:  A Kutlin; P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

10.  Recurrent genitourinary chlamydial infections in sexually active female adolescents.

Authors:  M J Blythe; B P Katz; B E Batteiger; J A Ganser; R B Jones
Journal:  J Pediatr       Date:  1992-09       Impact factor: 4.406

View more
  26 in total

1.  Proteomic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells.

Authors:  Robert E Molestina; Jon B Klein; Richard D Miller; William H Pierce; Julio A Ramirez; James T Summersgill
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Temporal expression of type III secretion genes of Chlamydia pneumoniae.

Authors:  Anatoly Slepenkin; Vladimir Motin; Luis M de la Maza; Ellena M Peterson
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 3.  Chlamydial persistence: beyond the biphasic paradigm.

Authors:  Richard J Hogan; Sarah A Mathews; Sanghamitra Mukhopadhyay; James T Summersgill; Peter Timms
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

Review 4.  Evolution to a chronic disease niche correlates with increased sensitivity to tryptophan availability for the obligate intracellular bacterium Chlamydia pneumoniae.

Authors:  Wilhelmina M Huston; Christopher J Barker; Anu Chacko; Peter Timms
Journal:  J Bacteriol       Date:  2014-03-28       Impact factor: 3.490

5.  Protein expression profiles of Chlamydia pneumoniae in models of persistence versus those of heat shock stress response.

Authors:  Sanghamitra Mukhopadhyay; Richard D Miller; Erin D Sullivan; Christina Theodoropoulos; Sarah A Mathews; Peter Timms; James T Summersgill
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Analysis of Chlamydia pneumoniae infection in mononuclear cells by reverse transcription-PCR targeted to chlamydial gene transcripts.

Authors:  Laura Mannonen; Eveliina Markkula; Mirja Puolakkainen
Journal:  Med Microbiol Immunol       Date:  2011-01-30       Impact factor: 3.402

7.  Tryptophan Codon-Dependent Transcription in Chlamydia pneumoniae during Gamma Interferon-Mediated Tryptophan Limitation.

Authors:  Scot P Ouellette; Kelsey J Rueden; Elizabeth A Rucks
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

8.  Initial characterization of Chlamydophila (Chlamydia) pneumoniae cultured from the late-onset Alzheimer brain.

Authors:  Ute Dreses-Werringloer; Mohammad Bhuiyan; Yinghao Zhao; Hervé C Gérard; Judith A Whittum-Hudson; Alan P Hudson
Journal:  Int J Med Microbiol       Date:  2008-09-30       Impact factor: 3.473

9.  Mixed infections with Chlamydia and porcine epidemic diarrhea virus - a new in vitro model of chlamydial persistence.

Authors:  Nicole Borel; Claudia Dumrese; Urs Ziegler; Andrea Schifferli; Carmen Kaiser; Andreas Pospischil
Journal:  BMC Microbiol       Date:  2010-07-27       Impact factor: 3.605

10.  The molecular basis for disease phenotype in chronic Chlamydia-induced arthritis.

Authors:  John D Carter; Herve C Gerard; Judith A Whittum-Hudson; Alan P Hudson
Journal:  Int J Clin Rheumtol       Date:  2012-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.